Provectus Pharmaceuticals Inc. Receives Fourth Pharmaceutical Patent For Anti-Cancer Agents

KNOXVILLE, Tenn., Jan. 31 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals, Inc. announced today it has received the Company's fourteenth U.S. patent (U.S. Patent 6,991,776), which is its fourth U.S. patent for its pharmaceutical products.

The patent covers use of the Company's anti-cancer pharmaceutical agent PV-10 for radiosensitization, augmenting coverage provided by the Company's earlier patents for cancer treatment and diagnostic imaging using CT, MRI and ultrasound. The Company is currently testing PV-10 in a chemoablative formulation, known as Provecta(TM), in clinical trials for treatment of metastatic melanoma and breast cancer.

"This patented technology facilitates use of our small-molecule, tumor- specific agent PV-10 for treatment of deep tissue and metastatic cancers," noted Craig Dees, Ph.D., Provectus CEO and co-inventor. "In pre-clinical studies, we've shown that PV-10 can dramatically enhance the effectiveness of conventional radiation therapy. Along with Provecta, which doesn't require use of radiation and allows for direct destruction of tumors, we believe PV-10 proves a versatile platform for a variety of pharmaceutical agents."

About Provectus Pharmaceuticals, Inc.

Provectus Pharmaceuticals, Inc. is a pioneering pharmaceutical company actively engaged in the design, development, and marketing of pharmaceutical technologies for the treatment of metastatic melanoma, breast cancer and liver cancer. In addition, Provectus is preparing to begin Phase 2 clinical studies for the Company's topical agent Xantryl(TM), a treatment for psoriasis.

The Company's offices and laboratory are located at 7327 Oak Ridge Highway, Suite A, Knoxville, TN 37931; telephone: 865 769 4011.

For more information, contact the Company at or visit the corporate Web site: .

This release and others statements issued or made from time to time by the company or its representatives contain comments that may constitute forward- looking statements. Those include statements regarding the intent, belief or current expectations of the company and members of its management teams, as well as the assumptions on which the statements are based. Prospective investors are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward- looking statements.

Provectus Pharmaceuticals, Inc.

CONTACT: Investors, Matt Clawson, Allen & Caron Inc., +1-212-691-8087,, for Provectus Pharmaceuticals, Inc.; or PeterCulpepper, Provectus Pharmaceuticals Inc., +1-865-769-4011,

Back to news